A Phase II Trial to Assess the Efficacy of Efavirenz as Second-line Monotherapy for the Treatment of Advanced Pancreatic Adenocarcinomas.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Efavirenz (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PANTER
Most Recent Events
- 07 Apr 2010 Biomarkers information updated
- 01 Sep 2009 New trial record